Frontlight ResearchEarly access
TerminatedPhase 2
Induction Chemo-Nivo in Unresectable Stage III NSCLC
Key facts
- Who runs it
- Ralph G Zinner
- Where
- Lexington, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 1 person enrolled
- Started
- 13 Dec 2023
- Ended
- 5 Jul 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- Nivolumab and Chemotherapy
- Nivolumab
- Post Induction Surgery
- Post Induction XRT
- Record updated
- 30 April 2025
- Why it stopped
- Slow accrual
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Squamous and non-squamous non-small cell lung cancer that is at baseline, unresectable stage IIIA-IIIC (8th edition AJCC) and not previously treated
- PD-L1 level needs to be measured with values 0-100% eligible
- EGFR/ALK/ROS1 Wild Type or unknown genetic alterations in these genes
- ECOG Performance Status ≤ 1
- Adequate organ and marrow function
- Adequate pulmonary reserve (e.g., FVC, FEV1, TLC, FRC, and DLCO) capable of tolerating the proposed lung resection
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen
- Clinical risk assessment of cardiac function using the New York Heart Association Functional Classification class 2B or better
- Ability to understand and the willingness to sign a written informed consent document
Who cannot take part
- Patients who have participated in a study with an investigational agent or device within 2 weeks of enrollment
- Any prior radiotherapy to the lung
- Any prior treatment for NSCLC
- Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
- Ongoing requirement for systemic corticosteroids greater than the equivalent of prednisone 10mg
- Any history of a severe hypersensitivity reaction to any monoclonal antibody
- Any history of allergy to the study drug components
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nivolumab or other agents used in study
- Any active or history of autoimmune disease (including any history of inflammatory bowel disease), or history of syndrome that required systemic steroids or immunosuppressive medications
- previous malignancies
- history of interstitial lung disease
- Use of any live vaccines against infectious diseases (e.g., influenza, varicella. etc.) within 4 weeks (28 days) of initiation of study therapy
- Active systemic infection requiring therapy
- Patients with uncontrolled intercurrent illness
- Patients with psychiatric illness/social situations that would limit compliance with study requirements
- primary tumors involving the esophagus
- pancoast tumors
- Patients cannot have primary tumors which would remain unresectable
- Patients requiring continuous supplemental oxygen
- Pregnant or lactating women
Where in United States
- University of KentuckyLexington, United States
About the trial
What the trial wants to find out
The purpose of this study is to determine the response rate, safety, and effectiveness of a combination therapy in patients with lung cancer.
The 2 groups in the trial
- Combination Chemotherapy and Nivolumab and SurgeryTreatment being tested
Patients with lung cancer receiving combination therapy with surgery
Treatment: Nivolumab and Chemotherapy, Nivolumab, Post Induction Surgery, and Post Induction XRT
- Combination Chemotherapy and Nivolumab and RadiationTreatment being tested
Patients with lung cancer receiving combination therapy with radiation
Treatment: Nivolumab and Chemotherapy, Nivolumab, and Post Induction XRT
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase II Study of Induction Platinum Doublet in Combination With Nivolumab Followed by Surgery or Concurrent Chemoradiation in Unresectable Stage IIIA-C Non-small Cell Lung Cancer (NSCLC)
- Record updated
- 30 April 2025